Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda), are increasingly prescribed for type 2 diabetes management and weight loss
Common side effects include nausea, vomiting, diarrhea or constipation, indigestion, stomach pain, and a decrease in appetite
Calculate the patients energy needs and caloric requirements based on individual factors
Lower-cost access during the boom helped thousands manage weight and related conditions, but the reckoning highlighted risks around quality consistency, supply stability, and treatment continuity
Lydia Alexander, M.D., president of the Obesity Medicine Association